Moderna price target lowered to $125 from $155 at Barclays

Barclays lowered the firm’s price target on Moderna to $125 from $155 and keeps an Overweight rating on the shares. The company’s research and development day provided mixed update, including major financial revisions with cost cutting and a cautious revenue outlook, the analyst tells investors in a research note. The firm says the near-term accelerated approval of individualized neoantigen therapies is “off the table.”